Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers,
but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor …

Tumor molecular profiling is a fundamental component of precision oncology, enabling the
identification of genomic alterations in genes and pathways that can be targeted …

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival …

Chromosomal rearrangements involving the NTRK1, NTRK2, and NTRK3 genes (NTRK
genes), which encode the high-affinity nerve growth factor receptor (TRKA), brain-derived …

Over the past decade, advances in molecular biology and genomics techniques have
revolutionized the diagnosis and treatment of cancer. The technological advances in tissue …

Clonal hematopoiesis (CH) is frequent in cancer patients and associated with increased risk
of therapy related myeloid neoplasms (tMN). To define the relationship between CH, …

Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer
care, an urgent need exists for a clinical support tool that distills the clinical implications …

The identification of specific genetic alterations as key oncogenic drivers and the development
of targeted therapies are together transforming clinical oncology and creating a pressing …

Background Inherited mutations in DNA-repair genes such as BRCA2 are associated with
increased risks of lethal prostate cancer. Although the prevalence of germline mutations in …

The AACR Project GENIE is an international data-sharing consortium focused on generating
an evidence base for precision cancer medicine by integrating clinical-grade cancer …